>when I said that GTCB fell on its face before, I was referring to when the FDA asked them for more clinical trial data and then GENZ abandoned them. I don't remember the name of the person I saw speak, and I'm pretty sure he's not there anymore.<
Whoever it was you saw, the person who was held responsible for the failure of GTC’s original ATryn program in CABG was the then-CEO Sandra Nusinoff Lehrman, who was canned in May, 2001. Lehrman is an MD with a background in AIDS research who probably never should have been the CEO of GTC.